Should you buy or sell Johnson & Johnson (JNJ)?

From the Sep 26, 2026 report · Read the full report

Hold

SellBuy

Team rating

Hold

Date: Sep 26, 2026
Price: $271.22

Johnson & Johnson (JNJ) maintains a Hold rating due to strong fundamentals, defensive positioning, and technical indicators. The company demonstrates robust profitability with a 25.74% ROE and 21.48% profit margin, supported by a 1.98% dividend yield. Technical analysis shows price above key moving averages but with weakening momentum, suggesting caution for new buyers.

Bull case

JNJ's strong fundamentals include 25.74% ROE and 21.48% profit margin, indicating efficient capital use and operational excellence.
The company's defensive nature is confirmed by a low beta of 0.235, making it suitable for risk-averse portfolios during market volatility.
Technical indicators show price trading above key moving averages (200 SMA at $238.26, 50 SMA at $264.28), confirming a bullish trend.
The Forward P/E of 22.34 offers a discount compared to TTM P/E of 31.50, suggesting potential value for growth-focused investors.
Recent positive pipeline developments, including RYBREVANT survival data and Tremfya Phase 4 success, strengthen JNJ's therapeutic portfolio.

Bear case

The PEG ratio of 2.84 suggests potential overvaluation relative to growth, cautioning against buying at current levels.
The MACD histogram shows declining momentum (-0.26), indicating slowing upward momentum and potential near-term consolidation.
A current ratio of 1.09 is marginally tight, raising concerns about short-term liquidity for aggressive credit analysts.
Rising Treasury yields (10Y at 5.18%) pressure high valuation stocks like JNJ, which trades at a rich P/E of 31.50 TTM.
Patent cliff risks and litigation exposure, noted in news coverage, present potential headwinds to future growth.

Risks

Rising interest rates could pressure JNJ's high price-to-book ratio (7.69x).
Regulatory risks in the pharmaceutical sector, including drug pricing reforms, may impact profitability.
The company's PEG ratio of 2.84 suggests overvaluation relative to growth, requiring careful valuation assessment.
A potential downward breakout below the Bollinger Lower Band ($262.83) could signal weakening momentum.
Litigation exposure, including opioid and infrastructure suits, remains a persistent risk factor.

The team's verdict

Johnson & Johnson (JNJ) maintains a Hold rating due to its strong fundamentals, defensive positioning, and technical indicators. The company demonstrates robust profitability with a 25.74% ROE and 21.48% profit margin, supported by a 1.98% dividend yield. Technical analysis shows price above key moving averages but with weakening momentum, suggesting caution for new buyers. The forward P/E of 22.34 offers a discount compared to TTM P/E of 31.50, but the PEG ratio of 2.84 suggests potential overvaluation relative to growth. Investors should consider adding gradually as price remains above $266.06 (derived as last close $271.22 minus ATR $5.16), while remaining cautious about rising interest rates and potential patent-related risks.

Frequently asked questions

Is it a good time to buy JNJ?

Our AI team rates Johnson & Johnson (JNJ) hold in its analysis of Sep 26, 2026. This page sums up the bull and bear arguments behind that call.

What is the main reason to buy JNJ?

JNJ's strong fundamentals include 25.74% ROE and 21.48% profit margin, indicating efficient capital use and operational excellence.

Sources: Yahoo Finance (prices, financial statements and analysts' estimates) and the U.S. Treasury (10-year yield). Indicators and valuation are computed without AI.

AI-generated informational content. Not financial advice or a personalised investment recommendation. Investing involves risk, including loss of capital.

Every week, in your inbox

Rating changes, the highest-conviction stocks and the week's best research. Free.